Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Their scientific platform is based on biological discoveries that govern tissue specialization and enable selective elimination of harmful proteins using small molecules. Biosplice has uncovered insights enabling Wnt pathway modulation that have unlocked the broad therapeutic potential of alternative splicing by targeting the CLK/DYRK family kinases. These kinases govern the selection of tissue-speciﬁc and disease-selective RNA splice-sites, thus deﬁning them as targets for drug therapy. Selectively reprogramming cellular behavior could lead to the discovery of new, potentially curative therapies for certain diseases. Biosplice’s clinical pipeline is focused on osteoarthritis and oncology, with early-stage programs in neurology and other areas of significant unmet medical need. Biosplice has developed six different compounds with fourteen different indications currently being explored in either preclinical or clinical trials. Cirtuvivint (SMO8502) has several oncologic indications.including metastatic castration-resistant prostate cancer (mCRPC),colorectal cancer (CRC), and Non-small cell lung carcinoma (NSCLC). Cirtuvivint works by targeting Pan-CLK/DYRK. This trial has completed Phase I and is expected to enter Phase II soon. CLK/DYRK is a family of protein kinases that potentially represent a druggable intervention point in alternative splicing-dependent cancers.